Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bioptik Technology's Enterprise Value is NT$1,371.9 Mil.
Bioptik Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$86.4 Mil. Therefore, Bioptik Technology's EV-to-FCF for today is 15.87.
The historical rank and industry rank for Bioptik Technology's EV-to-FCF or its related term are showing as below:
ROCO:4161'
s EV-to-FCF Range Over the Past 10 Years
Min: -229 Med: -15.37 Max: 700.92
Current: 16.11
During the past 13 years, the highest EV-to-FCF of Bioptik Technology was 700.92. The lowest was -229.00. And the median was -15.37.
ROCO:4161's EV-to-FCF is ranked better than 68.54% of 410
companies
in the Medical Devices & Instruments industry
Industry Median: 23.64
vs ROCO:4161: 16.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bioptik Technology's PE Ratio (TTM) for today is calculated as:
Bioptik Technology's share price for today is NT$22.45.
Bioptik Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bioptik Technology EV-to-FCF Related Terms
Bioptik Technology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bioptik Technology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioptik Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's EV-to-FCF falls into.
Bioptik Technology's current Enterprise Value is NT$1,371.9 Mil.
Bioptik Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$86.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a EV-to-FCF of 15.87 as of Sep. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioptik Technology and its competitors. According to the industry distribution chart, Bioptik Technology ranks #129 out of 410 companies in the Medical Devices & Instruments industry, placing it in the top 31.5%.
Is Bioptik Technology's EV-to-FCF too high?
Bioptik Technology's current EV-to-FCF is 15.87. The Medical Devices & Instruments industry median EV-to-FCF is 23.64. Bioptik Technology's value of 15.87 is 32.9% below this industry median. Based on the distribution chart, Bioptik Technology ranks #129 out of 410 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #129 out of 410 companies for EV-to-FCF. This puts Bioptik Technology in the upper half of its industry. The industry median EV-to-FCF is 23.64. Bioptik Technology's value of 15.87 is 32.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.64, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioptik Technology's current EV-to-FCF of 15.87 is 32.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bioptik Technology and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current EV-to-FCF is 15.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$29.78, compared to a current price of NT$22.45 — trading 24.6% below its estimated fair value. The current EV-to-FCF is 15.87 and 32.9% below the Medical Devices & Instruments industry median of 23.64. Bioptik Technology's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current EV-to-FCF is 15.87 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$22.45 is trading 24.6% below its estimated GF Value™ of NT$29.78.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
EV-to-FCF: 15.87
GF Value™: NT$29.78 vs. price of NT$22.45 (24.6% below fair value)
Industry Position: 32.9% below the Medical Devices & Instruments median (#129 of 410)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
71GF Score
Get the complete analysis for ROCO:4161
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
